Posted by: Laurence Harmon on 6/26/2008 | 0 Comments

According to a recent study, a low dose of dietary resveratrol (the ingredient found in red wine) partially mimics caloric restriction and retards aging parameters in mice.

Although not yet proven in humans, lab rodents in an extreme caloric restricted diet have had extended life spans by up to 30 percent.

A recent study conducted at Harvard University in the U.S.A. again confirms the benefits of drinking moderate amounts of red wine. The study, using laboratory rats, confirmed earlier studies at other universities that red wine contains ingredients that reduce levels of cholesterol in the blood stream, reduces risks of some forms of cancer, and even helps prevent the onset of Alzheimer’s disease.

Bottom line:  Red wine may be a potent antidote to Alzheimer's!

The robot enables service providers to customize and offer various services to their customers.  Robots provide social interactions and remote visits with distant friends, relatives and doctors, remote telemedicine, cognitive prosthesis, daily reminders, and more.

Beyond professional applications, the era of personal robotics is now underway.  Robosoft believes that its service robots called "robuters" will be part of everyday life within five years. According to forecasts by the Japan Robotics Association, the worldwide personal and service robotics market will reach $17 billion by 2010.  

Posted by: Laurence Harmon on 6/21/2008 | 0 Comments

The Congressional Budget Office pegs the annual savings from generic drugs in the U.S. alone at $8 billion to $10 billion.

On Feb. 6, the $3 billion-per-year best seller Fosamax, the leading treatment for osteoporosis, lost its patent protection.  Its maker, Merck (MRK), plans to sell an “authorized generic” with Watson Pharmaceuticals (WPI) to compete with similar generics from Teva Pharmaceuticals (TEVA) and Barr Pharma (BRL). All this competition will mean the price of alendronate (the generic name for Fosamax)—currently about $90 per month—should drop by 60% to 70%.

Here’s a look at some other popular drugs that lose patent protection in 2008.

  • Fosamax
  • Advair
  • Serevent
  • Sonata
  • Effexor XR
  • Lamictal
  • Topamax
  • Casodex
  • Trusopt
  • Zerit
1 2 3 4 5 6 7 8 9 10  ...  Go to Page: